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Benign as well as malignant tumour tissues of the breast demonstrate higher fluorescence intensity (FI) than normal breast tissue after
application of a photosensitiser. As a follow-up study, we evaluated the FI of metastatic sentinel lymph nodes and metastatic axillary
lymph nodes compared to nonmetastatic sentinel and axillary lymph nodes in patients with breast cancer. In all, 11 patients received
30mg 5-aminolevulinic acid (ALA)kg
 1 bodyweight orally 3h prior to surgery. The sentinel lymph node was marked with Nanocoll
s
preoperatively and with a blue dye intraoperatively. Tumour excision, excision of the sentinel lymph node and an axillary lymph node
dissection were performed during the same surgical session. The operation site was illuminated with blue light (400nm) to obtain
macroscopic tissue characterisation of fluorescence. Tissue samples were stored protected from light, and analysed using a
fluorescence microscope. Results were correlated with histopathology. In all, 14 sentinel lymph nodes, seven axillary lymph nodes and
seven primary tumours were analysed. Metastatic sentinel lymph nodes demonstrated a statistically significant higher FI than
nonmetastatic sentinel lymph nodes (2630 vs 526, Po0.0001). The FI of metastatic sentinel lymph nodes, of metastatic axillary lymph
nodes and of the primary tumour were comparably high, and were statistically significantly higher compared to the normal mammary
tissue. Intraoperatively, only in a few cases, it was possible to recognise the metastatic sentinel lymph node macroscopically with blue
light. Our study indicates that photodynamic diagnosis with ALA has a potential in the diagnosis and detection of the sentinel lymph
node in patients with breast cancer, and is worth to be further investigated and developed for intraoperative photodynamic diagnosis
and possibly therapy.
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Photodynamic therapy (PDT) and diagnosis (PDD) is of increasing
interest in oncology, especially in gynaecologic malignancies as
well as in patients with breast cancer. Photodynamic therapy and
PDD were introduced three decades ago, with a major focus on
gynaecology (Dougherty and Marcus, 1992). Systemic or topical
application of the prodrug 5-aminolevulinic acid (ALA) induces
the endogenous synthesis and accumulation of large quantities of
the endogenous photosensitiser protoporphyrin IX (PpIX) in
many tissues, especially derivatives of epithelia such as carcino-
mas. Exposure to activating red light of 635nm produces a
phototoxic effect, resulting in tumour cell necrosis. Topical ALA-
based PDT has been reported effective for the treatment of a
variety of dermatological diseases including cutaneous superficial
and nodular basal cell carcinoma, Bowen’s disease and actinic
(solar) keratoses (Morton et al, 2001). Local intrauterine applica-
tion of ALA has also been used for selective endometrial ablation
in animal models and in human clinical studies (Steiner et al, 1995,
1996b; Wyss et al, 2001). By the use of blue light at 400nm, PpIX
induced by ALA has been applied as a fluorescence detection
marker for photodiagnosis of cancer and dysplastic conditions of
the urinary bladder and other organs (Kennedy et al, 1996).
Application of ALA has been developed for detection of alterations
in gynaecological tissues including the endometrium, the vulva
and skin metastasis of breast cancer (Fehr et al, 1996, 2001; Steiner
et al, 1996a). Photodynamic therapy provides an alternative
treatment modality using a second-generation photosensitiser
and laser light to induce selective tumour necrosis (Wyss et al,
2001).
In a recent feasibility study applying ALA orally, we demon-
strated that mammary tumour tissue examined by fluorescence
microscopy presented significantly higher fluorescence intensity
(FI) than the normal surrounding tissue. Autofluorescence of the
normal breast tissue was very low. It was possible to visualise
tumour tissue using blue light intraoperatively (Ladner et al,
2001a). As the minimal invasive staging of the sentinel lymph node
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lfor potential metastases is of increasing importance, we focused
our consecutive study on the photodynamic detection and
diagnosis of the sentinel lymph node in patients with breast
cancer.
The purpose of this follow-up study was to evaluate
the effectiveness of oral application of ALA for PDD of the
sentinel lymph node in patients with breast cancer. Fluorescence
intensity in the primary breast tumour, in the sentinel lymph
nodes and in axillary lymph nodes was analysed by fluorescence
microscopy.
MATERIALS AND METHODS
Patients
The study was performed at the Women’s hospital Fontana, Chur,
Switzerland, and was approved by the ethical committee of the
Canton Graubuenden Chur, Switzerland (Study 18/01, October
2001). A total of 11 patients undergoing breast-conserving surgery
for invasive breast cancer were included in this study after having
signed the informed consent form. All patients underwent the
sentinel lymph node mapping with Nanocoll
s (AmershamHealth
AG, Wa ¨denswil, Switzerland) preoperatively. Intraoperatively, a
blue dye (Bleu Pathenthe V, 2.5%, Guerbet, Roissy, France) was
injected around the tumour to identify the sentinel lymph node.
The exclusion criteria were acute porphyria, elevated liver
enzymes, renal or hepatic insufficiency, intake of hypericin-
containing medication and pregnancy.
ALA and patient protection
d-ALA (ASAT AG, Zug Switzerland) was administered orally at a
concentration of 30mg per kg bodyweight, solved in 50cl of water,
3h prior to surgery. Patients were given 8mg Ondansetron
(Zofran
s, GlaxoSmithKline AG, Mu ¨nchenbuchsee, Switzerland)
together with d-ALA. A sun blocker (Spirig
s, Egerkingen,
Switzerland) was applied to the face and neck, and covered with
a micropigment cream, which has shown good results in light
protection during photosensitisation with ALA and Foscan
s
(Biolitec Pharma Ltd, Edingburgh, UK) (Schwarz et al, 2001). In
addition, patients were protected from direct light for 24h after
application of ALA.
Tissue conservation
Immediately after excision, the malignant tumour, the sentinel
lymph node as well as the other lymph nodes were protected from
light in sealed bottles, and transported immediately to the
Pathology Department, Cantonal Hospital Chur, Switzerland. The
primary tumour tissue, the sentinel lymph node and other lymph
nodes were carefully divided into two parts by a surgical blade, and
were protected from light. One part underwent the regular
pathological diagnostic procedures. The other part was stored
and frozen in a light-protected container at  801C. In a dark room,
10 cryosections of 10mm thickness were prepared from tumour
tissue, sentinel lymph node and axillary lymph nodes. The sections
were wrapped in aluminium foil, sealed in boxes protecting against
drying out and photobleaching, and then again stored at  801C.
These slides were transported on dry ice to the Research Division
of Gynaecology, University Hospital, Zurich. After fluorescence
microscopy, the analysed sections were additionally stained with
haematoxylin and eosin and microscopically analysed to obtain
histological information in this part of the tissue.
Fluorescence microscopy and image acquisition
Tissue sections were analysed by fluorescence microscopy. From
every tumour and corresponding tissue, at least five sections were
analysed. Fluorescence imaging was performed with a CCD camera
system (photometrics, Tucson, AZ, USA) with a Kodak KAF 1600
chip coupled to a Leitz DMR/E fluorescence microscope (Leica,
Glattbrugg, Switzerland). Light from a 50mW HO mercury lamp
was filtered through a 405–420nm broad-bandpass filter to
provide excitation light. A dichroic mirror reflected the excitation
light onto the sample and transmitted the fluorescence emission
through a 635–655nm broad-bandpass filter onto the detector.
Instrument control, image acquisition and processing were
performed using the Image Pro Plus software (MediaCybernetics,
Silver Spring, MA, USA). Micrographs were acquired with an
integration time of 20s. All optical settings of the microscope were
kept constant for all image acquisitions, in order to be able to
compare the acquired information.
PDD during surgery
During the surgical procedure, intraoperative PDD was performed.
A laparoscopic D-light system, 20133201 (Karl Storz GmbH,
Figure 1 Fluorescence micrograph ( 20) of metastatic SLN (A) versus nonmetastatic SLN tissue (B). The FI of metastatic tissue is more intense than the
FI of nonmetastatic tissue.
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observatory filter, analogous to the PDD-Cystoskope 27005AIA
was used to illuminate the operation field and the sentinel lymph
node. Using a PDD camera system, the tissue fluorescence was
documented with a video system.
Statistical analysis
For statistical analysis, Statview
s for Microsoft for Windows
s was
used. The FI of primary breast carcinoma, metastatic and
nonmetastatic sentinel lymph nodes as well as metastatic and
nonmetastatic axillary lymph nodes were compared using the two-
sided Student’s t-test.
In the illustrations (Figure 1), we used the Box–Whisker plots.
Parametric and nonparametric summary statistics are presented
for each variable. Box plots graphically show the central location
and scatter/dispersion of the observations of samples. The median,
the lower and upper quartiles, and confidence interval around the
median are illustrated. The vertical lines show the requested
nonparametric percentile ranges.
RESULTS
FI of the primary breast cancer compared with normal
breast tissue
Sections of seven primary breast tumours were evaluated using
the fluorescence microscope. The histological report of the
seven primary tumours revealed six invasive ductal and one
invasive lobular breast carcinoma. Tumour size ranged
between 1.5 and 4.5cm. The breast tumour tissues of patients
2, 5, 6, 8 and 11 could not be analysed due to problems of
tissue conservation and technical problems with microscopic
analysis. Patient 9 had bilateral breast carcinoma, and it was
possible to analyse the tissue of both sides (Table 1). All primary
breast cancers showed a highly significant difference (Po0.0001)
in FI compared to the surrounding normal mammary tissue
(Figure 1). The mean value of tumour tissue was five times higher
than the surrounding normal mammary tissue, and ranged from
832 to 4029 (relative values, Table 1). The normal mammary tissue
ranged from 130 to 337. One patient with extensive disease (large
primary tumour and three positive lymph nodes) showed the
highest FI of the primary tumour (4029, patient 7, Table 1). To
overcome the fact that FI varies among the patients, a ratio
between the FI of tumour and normal mammary tissue was
calculated and compared, yielding the same statistically significant
results.
FI of the nonmetastatic and metastatic sentinel lymph
nodes and the nonmetastatic and metastatic axillary lymph
nodes
Sections of a total of 21 lymph nodes were examined. In all, 14
lymph nodes were identified as sentinel lymph nodes intraopera-
tively (Table 2). Histopathology diagnosed seven metastatic
sentinel lymph nodes, seven disease-free sentinel lymph nodes,
two metastatic axillary lymph nodes and five disease-free axillary
lymph nodes (Table 1). Fluorescence intensity of the metastatic
sentinel lymph nodes was significantly higher than that of
nonmetastatic sentinel lymph nodes (Po0.0001) (Figures 1 and
2). Fluorescence intensity of metastatic axillary lymph nodes was
also significantly higher than that of nonmetastatic axillary lymph
nodes (Po0.0001) (Figures 1 and 2). Metastatic axillary and
metastatic sentinel lymph nodes did not show a significant
difference in FI (Figures 1 and 2). Also, nonmetastatic sentinel
lymph nodes and nonmetastatic axillary lymph nodes did not
differ in FI (Figure 2). Figure 3 gives an example for the
microscopical findings of a metastatic and a nonmetastatic sentinel
lymph node.
FI of the primary breast cancer compared with metastatic
and non-metastatic lymph node tissue
FI of the primary breast cancer tissue and metastatic lymph node
tissue was comparably high. Fluorescence intensity of primary
breast cancer tissue was significantly higher than the one of the
nonmetastatic lymph node tissue (Po0.0001) (Figure 1).
Table 1 Fluorescence intensity of tumour and lymph node tissue,
correlated with histopathology
Patient Mean FI Ratio Histopathology
1 832.83 6.41 Tumour
1 2590.50 19.93 Metastatic SLN
1 562.67 4.33 Nonmetastatic ALN
3 1682.33 4.99 Tumour
3 330.00 0.38 Nonmetastatic SLN
4 1771.67 12.75 Tumour
4 704.00 5.06 Nonmetastatic SLN
4 517.67 3.72 Nonmetastatic ALN
5 334.83 1.77 Nonmetastatic SLN
5 412.83 2.18 Nonmetastatic SLN
6 519.83 1.66 Nonmetastatic SLN
6 539.33 1.72 Nonmetastatic ALN
7 4029.83 12.07 Tumour
7 3921.50 11.74 Metastatic ALN
7 3954.00 11.84 Metastatic SLN
7 3341.33 10.00 Metastatic SLN
8 814.17 3.11 Nonmetastatic SLN
9 1966.17 7.28 Tumour
9 3824 14.17 Tumour
9 477.33 1.77 Nonmetastatic ALN
9 402.67 1.49 Nonmetastatic ALN
9 2072 7.67 Metastatic SLN
9 567.50 2.10 Nonmetastatic SLN
10 2106.50 9.80 Tumour
10 1640.67 7.63 Metastatic SLN
11 2852.17 11.41 Metastatic SLN
11 1958.67 7.83 Metastatic SLN
11 3300.33 13.20 Metastatic ALN
SLN¼sentinel lymph node; ALN¼axillary lymph node; ratio indicates the mean FI of
tumour or lymph node tissue over the FI of normal breast tissue.
Table 2 Mean values of FI of subgroups with the corresponding standard deviation, and confidence intervals
Group n Mean Standard deviation Standard error 95% Confidence interval of the mean Median
Tumour 7 2316.2 1174.5 443.9 1230.0–3402.5 1966.1
Nonmetastatic SLN 7 526.2 184.5 69.7 355.5–696.8 519.8
Metastatic SLN 7 2629.9 821.7 310.6 1869.9–3389.8 2590.5
Nonmetastatic ALN 5 499.9 62.8 28.1 421.9–577.9 517.7
Metastatic ALN 2 3610.9 439.2 310.6  335.4–7557.3 3610.9
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Only a limited evaluation of the macroscopic fluorescence was
possible using the laparoscopic D-light system intraoperatively. Six
sentinel lymph nodes showed fluorescence intraoperatively. In
three of the six lymph nodes, metastatic tumour tissue was found
by histopathology. Seven nonmetastatic lymph nodes did not show
any fluorescence. Five of a total of 11 tumours showed fluorescence
intraoperatively. The tumour cavity in all patients was lightened
during the operation and did not show any fluorescence, as the
tumour tissue was excised with negative margins at histopathology
at the first intent.
Side effects from oral application of ALA
Oral application of ALA at a concentration up to 60mg per kg
bodyweight is known to have little and short-lived side effects
(24h). We used a concentration of 30mg per kg bodyweight.
Applying this concentration and all the safety procedures, none of
the 11 patients developed notable side effects. Two patients had
slightly elevated liver enzymes postoperatively, none of the
patients had nasal swelling, oedema or erythema of the skin.
DISCUSSION
Lymphatic mapping and identification of the sentinel lymph node
in patients with breast cancer is rapidly approaching the standard
of care. The driving forces behind this rapid acceptance are mainly
a result of the accuracy of the procedure with a significant decrease
in morbidity over the old standard of care, a level I and II node
dissection (Jakub et al, 2003). It is of increasing interest to quickly
detect the sentinel lymph node and to know whether there it is
metastasised in order to decide whether axillary lymph node
dissection becomes necessary. Our initial set-up for PDD after
orally applied ALA (Ladner et al, 2001a) was successfully
confirmed in this follow-up study for the demonstration of FI in
tumour tissue. This was possible with an even lower ALA
concentration of 30mgkg
 1 bodyweight. Fluorescence intensity
of all tumour samples was significantly higher than FI of the
surrounding normal mammary tissue, and autofluorescence of
normal tissue was very low. These findings confirm our earlier
results. One limitation of our study is the small patient population
of 11 included patients. Nevertheless, with the analysis of 21 lymph
nodes it was possible to yield statistically significant results.
In this study, we found significantly higher FI in metastatic
sentinel lymph nodes as well as in other metastatic axillary lymph
nodes compared to the normal breast tissue and to nonmetastatic
sentinel and axillary lymph node tissue. Intraoperatively, three
metastatic lymph nodes and five of the primary breast tumours
showed fluorescence using a laparoscopic D-light system. As the
laparoscopic D-light system is usually not used for open surgery, it
was difficult to assess the macroscopic fluorescence adequately.
Based on our results, we believe that it is worth emphasising on the
development of an optimal light system to detect the fluorescence
of the sentinel lymph node in the axilla. With improved sensor
technology (Wagnieres et al, 1998; Bigio et al, 2000), it might
Figure 2 Illustration of significance levels for all groups observed. Two-sided t-test was used to determine significant differences. All nonmetastatic
subgroups are significantly different from the tumour tissue as well as metastatic lymph nodes.
Figure 3 Box–Whisker plot of tumour and lymph node groups. Graphs
on the left side illustrate parametric, on the right side nonparametric
observations.
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axillary sentinel lymph node in patients with breast cancer. Even
intraoperative PDT may be envisioned once the sentinel lymph
node has been identified by PDD carrying tumour metastasis. This
would offer new minimal invasive treatment modalities after
diagnosing the extent of disease.
We found a large variation in FI among our patients. It seems
notable that, in patients with more extensive disease (Table 1,
patient 7 and patient 11), FI was considerably higher than in
patients with local disease. Many factors influence the amount of
PpIX accumulating in the tissue. Metabolism of ALA varies from
one patient to another. With a higher turnover of cells, FI might
increase.
Various ways to apply different photosensitisers have been
studied. Photodynamic treatment of local chest wall recurrence of
breast cancer offered a minimal-invasive, outpatient treatment
modality, with few side effects but prolonged healing phase (Wyss
et al, 2001). 5-Aminolevulinic acid is known to produce side effects
such as nausea and phototoxic reaction of the light-exposed skin
(Webber et al, 1997; Ladner et al, 2001b). Up to 60mg per kg
bodyweight, ALA is associated with minimal side effects in patients
undergoing surgery. Based on the results of the recent study
performed at our institution in which pranasal swelling was a
common finding (Ladner et al, 2001a), we decided to administer
ALA at a dosage of 30mg per kg bodyweight. With this dosage, we
had no notable side effects and only in two patients transient
elevated liver enzymes were observed. One might hypothesise that
a higher dosage would result in easier macroscopic detection of
tumour tissue or the sentinel lymph node with the D-light system.
However, microscopic FI of the tissue was measurable without
problems in the cases reported in this study.
Our study indicates that PDD with ALA has a potential in the
detection and diagnosis of the diseased sentinel lymph node in
patients with breast cancer. This technique is worth to be further
investigated and developed for intraoperative PDD and possible
therapy.
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